Keybank National Association OH purchased a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 22,880 shares of the specialty pharmaceutical company’s stock, valued at approximately $915,000.

Several other hedge funds have also modified their holdings of SUPN. UBS Asset Management Americas Inc. grew its stake in shares of Supernus Pharmaceuticals by 77.4% during the first quarter. UBS Asset Management Americas Inc. now owns 17,737 shares of the specialty pharmaceutical company’s stock worth $555,000 after acquiring an additional 7,737 shares during the last quarter. OppenheimerFunds Inc. purchased a new stake in Supernus Pharmaceuticals in the first quarter valued at approximately $205,000. Teachers Advisors LLC boosted its position in Supernus Pharmaceuticals by 1.8% in the first quarter. Teachers Advisors LLC now owns 436,121 shares of the specialty pharmaceutical company’s stock valued at $13,651,000 after buying an additional 7,861 shares during the last quarter. Vanguard Group Inc. boosted its position in Supernus Pharmaceuticals by 6.6% in the first quarter. Vanguard Group Inc. now owns 2,516,335 shares of the specialty pharmaceutical company’s stock valued at $78,762,000 after buying an additional 156,094 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Supernus Pharmaceuticals by 18.3% in the first quarter. Geode Capital Management LLC now owns 447,824 shares of the specialty pharmaceutical company’s stock valued at $14,015,000 after buying an additional 69,395 shares during the last quarter. Institutional investors and hedge funds own 96.45% of the company’s stock.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $47.60, for a total value of $2,380,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Stefan K.F. Schwabe sold 95,000 shares of the business’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $46.59, for a total value of $4,426,050.00. The disclosure for this sale can be found here. Insiders sold 150,000 shares of company stock valued at $7,055,350 over the last three months. 6.70% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Keybank National Association OH Purchases Shares of 22,880 Supernus Pharmaceuticals, Inc. (SUPN)” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.dailypolitical.com/2017/11/15/keybank-national-association-oh-purchases-shares-of-22880-supernus-pharmaceuticals-inc-supn.html.

Supernus Pharmaceuticals, Inc. (SUPN) opened at $37.20 on Wednesday. Supernus Pharmaceuticals, Inc. has a twelve month low of $20.55 and a twelve month high of $50.04. The stock has a market capitalization of $1,937.71, a P/E ratio of 35.66, a price-to-earnings-growth ratio of 1.60 and a beta of 1.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The company had revenue of $80.40 million during the quarter, compared to the consensus estimate of $78.74 million. The firm’s revenue was up 41.5% compared to the same quarter last year. research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.07 EPS for the current fiscal year.

A number of equities research analysts recently commented on SUPN shares. Piper Jaffray Companies reiterated a “hold” rating and issued a $41.00 target price on shares of Supernus Pharmaceuticals in a research report on Tuesday, September 26th. Cantor Fitzgerald reiterated a “buy” rating and issued a $49.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, September 27th. Stifel Nicolaus reiterated a “buy” rating and issued a $47.00 target price (up previously from $36.00) on shares of Supernus Pharmaceuticals in a research report on Tuesday, July 18th. BidaskClub upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 17th. Finally, FBR & Co started coverage on Supernus Pharmaceuticals in a research report on Thursday, October 19th. They issued a “buy” rating and a $53.00 target price on the stock. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $49.60.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.